Balchem (NASDAQ:BCPC) Rating Lowered to Hold at BidaskClub

BidaskClub cut shares of Balchem (NASDAQ:BCPC) from a buy rating to a hold rating in a research report report published on Saturday morning, BidAskClub reports.

Several other brokerages have also weighed in on BCPC. Zacks Investment Research lowered Balchem from a hold rating to a sell rating in a research report on Monday, August 5th. HC Wainwright reaffirmed a buy rating and issued a $95.00 target price (down from $110.00) on shares of Balchem in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $108.75.

Shares of BCPC opened at $94.33 on Friday. The company has a current ratio of 3.73, a quick ratio of 2.63 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $3.05 billion, a P/E ratio of 31.34 and a beta of 1.17. The stock’s fifty day simple moving average is $92.68 and its 200 day simple moving average is $95.65. Balchem has a twelve month low of $73.16 and a twelve month high of $116.93.



Balchem (NASDAQ:BCPC) last issued its earnings results on Thursday, August 1st. The basic materials company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.08. The business had revenue of $161.60 million for the quarter, compared to analyst estimates of $163.14 million. Balchem had a return on equity of 13.87% and a net margin of 12.27%. The business’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period last year, the company posted $0.76 EPS. Sell-side analysts predict that Balchem will post 3.06 earnings per share for the current year.

In related news, VP David F. Ludwig sold 12,750 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $90.00, for a total value of $1,147,500.00. Following the completion of the sale, the vice president now directly owns 21,038 shares in the company, valued at approximately $1,893,420. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Scott C. Mason purchased 3,000 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was bought at an average price of $84.74 per share, with a total value of $254,220.00. Following the completion of the acquisition, the vice president now owns 12,524 shares in the company, valued at approximately $1,061,283.76. The disclosure for this purchase can be found here. Company insiders own 1.28% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in Balchem by 1.0% in the 2nd quarter. BlackRock Inc. now owns 4,712,524 shares of the basic materials company’s stock valued at $471,110,000 after purchasing an additional 47,908 shares in the last quarter. Wasatch Advisors Inc. increased its holdings in Balchem by 6.0% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,306,898 shares of the basic materials company’s stock valued at $130,651,000 after purchasing an additional 74,061 shares in the last quarter. Conestoga Capital Advisors LLC increased its holdings in Balchem by 2.6% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 822,800 shares of the basic materials company’s stock valued at $82,255,000 after purchasing an additional 20,812 shares in the last quarter. Clearbridge Investments LLC increased its holdings in Balchem by 0.4% in the 1st quarter. Clearbridge Investments LLC now owns 560,657 shares of the basic materials company’s stock valued at $52,029,000 after purchasing an additional 2,147 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Balchem by 1.0% in the 2nd quarter. Northern Trust Corp now owns 478,505 shares of the basic materials company’s stock valued at $47,837,000 after purchasing an additional 4,940 shares in the last quarter. Hedge funds and other institutional investors own 86.42% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.

Read More: What is a recession?

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.